Literature DB >> 25831894

[Chymotripsin-like activity and subunit composition of proteasomes in human cancers].

I V Kondakova, L V Spirina, V D Koval, E E Shashova, E L Choinzonov, E V Ivanova, L A Kolomiets, A L Chernyshova, E M Slonimskaya, E A Usynin, S G Afanasyev.   

Abstract

Activity of the proteasome, polyfunctional enzymatic complex, is known to undergo changes during cancer development. This phenomenon is, probably, caused by the changes in subunit composition of proteasomes. In present work, we studied chymotrypsin-like activity of proteasomes, subunit composition and their association in breast cancer, head and neck squamous cell carcinoma, endometrial cancer, renal cancer, bladder cancer, stomach cancer and colorectal cancer. The increase of proteasome activity was revealed in most cancer tissues compared with adjacent tissues except for the renal cell carcinoma. Changes in proteasome activity in cancer tissues compared with correspondent normal tissues were accompanied by modification of its subunit composition. High proteasome activity was observed in combination with an increased expression of immune subunits and/or proteasome activator PA28, associated with activity of 20S proteasome. In breast cancer, head and neck squamous cell carcinoma, bladder cancer, stomach cancer and colorectal cancer we additionally found higher expression of Rpt6 subunit of 26S proteasome. Correlations between chymotrypsin like proteasome activity and subunit expressions were found in human cancer tissues. In summary, we suggest that proteasome ac- tivation and changes in its subunit composition plays an important role in cancer pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25831894

Source DB:  PubMed          Journal:  Mol Biol (Mosk)        ISSN: 0026-8984


  7 in total

1.  Potential use of chymotrypsin-like proteasomal activity as a biomarker for prostate cancer.

Authors:  Xinghua Wei; Weiwei Zeng; Keji Xie; Pengfei Diao; Ping Tang
Journal:  Oncol Lett       Date:  2018-02-02       Impact factor: 2.967

2.  Proteasome functioning in breast cancer: connection with clinical-pathological factors.

Authors:  Elena E Shashova; Yulia V Lyupina; Svetlana A Glushchenko; Elena M Slonimskaya; Olga V Savenkova; Alexey M Kulikov; Nikolay G Gornostaev; Irina V Kondakova; Natalia P Sharova
Journal:  PLoS One       Date:  2014-10-17       Impact factor: 3.240

3.  The levels of serine proteases in colon tissue interstitial fluid and serum serve as an indicator of colorectal cancer progression.

Authors:  Yingying Xie; Lechuang Chen; Xiaolei Lv; Guixue Hou; Yang Wang; Cuicui Jiang; Hongxia Zhu; Ningzhi Xu; Lin Wu; Xiaomin Lou; Siqi Liu
Journal:  Oncotarget       Date:  2016-05-31

4.  PEG-Poly(1-Methyl-l-Tryptophan)-Based Polymeric Micelles as Enzymatically Activated Inhibitors of Indoleamine 2,3-Dioxygenase.

Authors:  George Lo Huang; Anqi Tao; Takuya Miyazaki; Thahomina Khan; Taehun Hong; Yasuhiro Nakagawa; Horacio Cabral
Journal:  Nanomaterials (Basel)       Date:  2019-05-09       Impact factor: 5.076

5.  Relation between Tetraspanin- Associated and Tetraspanin- Non- Associated Exosomal Proteases and Metabolic Syndrome in Colorectal Cancer Patients

Authors:  Elena A Tugutova; Svetlana N Tamkovich; Marina R Patysheva; Sergey G Afanas’ev; Anastasia A Tsydenova; Alina E Grigor’eva; Elena S Kolegova; Irina V Kondakova; Natalia V Yunusova
Journal:  Asian Pac J Cancer Prev       Date:  2019-03-26

6.  Tripartite-motif family genes associated with cancer stem cells affect tumor progression and can assist in the clinical prognosis of kidney renal clear cell carcinoma.

Authors:  Guangzhen Wu; Yingkun Xu; Lin Li; Jianyi Li; Ningke Ruan; Jian Dong; Zhuyuan Si; Qinghua Xia; Qifei Wang
Journal:  Int J Med Sci       Date:  2020-10-18       Impact factor: 3.738

Review 7.  Estrogen Receptors and Ubiquitin Proteasome System: Mutual Regulation.

Authors:  Irina V Kondakova; Elena E Shashova; Evgenia A Sidenko; Tatiana M Astakhova; Liudmila A Zakharova; Natalia P Sharova
Journal:  Biomolecules       Date:  2020-03-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.